All In Biotech

Drug Trial Radar · NCT07752550

Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer

Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer: An Exploratory Clinical Study

Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

Jul 30, 2028

Study completion Jul 30, 2029

Sponsor

Lead sponsor
Harbin Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the efficacy and safety of Retlirafusp alfa in combination with chemotherapy or fluzoparib for early-stage and advanced triple-negative breast cancer.

Conditions

  • Triple-Negative Breast Cancer (TNBC)

Interventions

  • Retlirafusp alfa+Nab-paclitaxel:Drug

    Retlirafusp alfa+Nab-paclitaxel

  • Retlirafusp alfa+FluzoparibDrug

    Retlirafusp alfa+Fluzoparib

  • Retlirafusp alfa+TP-ACDrug

    Retlirafusp alfa+TP-AC

  • Retlirafusp alfa+FluzoparibDrug

    Retlirafusp alfa+Fluzoparib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Late-Stage Cohort-Objective Response RateTime frame: Assessed every 6 weeks (every 2 cycles) during treatment until disease progression, death, or loss to follow-up. Analysis cutoff at 6 months.
  2. Neoadjuvant Cohort-tpCR (ypT0/is ypN0)Time frame: Surgery performed 2-6 weeks after completing 8 cycles (≈24 weeks) of neoadjuvant therapy; pathological assessment post-surgery. Analysis cutoff at 6 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.